{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["71"],"submitter":["Huang Y"],"pubmed_abstract":["Cisplatin-based chemotherapy causes hearing loss in 40-60 % of all patients, yet effective preventative options remain limited. Building on prior animal studies, we demonstrate that oral administration of AZD5438, a potent and selective CDK2 inhibitor, provides dose-dependent protection against hearing loss in a clinically relevant multi-dose cisplatin mouse model. Protective doses (4.7 and 9.4 mg/kg b.i.d.) fall within the human-equivalent maximum tolerated dose range established in AstraZeneca trials, and exhibit plasma pharmacokinetics comparable to those in humans. Importantly, AZD5438 at 9.4 mg/kg b.i.d. does not reduce cisplatin's anti-tumor efficacy in a testicular cancer xenograft model, consistent with in vitro findings. These results support AZD5438 as a promising candidate for c"],"journal":["Neoplasia (New York, N.Y.)"],"pagination":["101250"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12634867"],"repository":["biostudies-literature"],"pubmed_title":["Oral AZD5438 is a clinically translatable otoprotectant against cisplatin-induced hearing loss."],"pmcid":["PMC12634867"],"pubmed_authors":["Vesanes E","Teitz T","Huang Y","Zuo J","Zhang X"],"additional_accession":[]},"is_claimable":false,"name":"Oral AZD5438 is a clinically translatable otoprotectant against cisplatin-induced hearing loss.","description":"Cisplatin-based chemotherapy causes hearing loss in 40-60 % of all patients, yet effective preventative options remain limited. Building on prior animal studies, we demonstrate that oral administration of AZD5438, a potent and selective CDK2 inhibitor, provides dose-dependent protection against hearing loss in a clinically relevant multi-dose cisplatin mouse model. Protective doses (4.7 and 9.4 mg/kg b.i.d.) fall within the human-equivalent maximum tolerated dose range established in AstraZeneca trials, and exhibit plasma pharmacokinetics comparable to those in humans. Importantly, AZD5438 at 9.4 mg/kg b.i.d. does not reduce cisplatin's anti-tumor efficacy in a testicular cancer xenograft model, consistent with in vitro findings. These results support AZD5438 as a promising candidate for c","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-06-05T17:46:48.048Z","creation":"2026-05-19T03:11:50.182Z"},"accession":"S-EPMC12634867","cross_references":{"pubmed":["41187663"],"doi":["10.1016/j.neo.2025.101250"]}}